HLB Pharmaceutical 2026 Q1: Revenue up 89% YoY, operating profit nearly equals full year 2025

Consolidated Q1 2026 revenue KRW 65.65 billion (up 89% YoY from KRW 34.65 billion), operating profit KRW 1.03 billion (similar to Q1 2025), net income KRW 0.72 billion
Subsidiary ShinHwa Advance (pharmaceutical distribution, acquired May 2025) contributed KRW 21.17 billion in Q1 revenue
Debt ratio improved to 33.56% from 36.38% at year-end 2025, low liquidity risk
R&D expense KRW 2.04 billion (3.36% of sales), pipeline includes long-acting injectables
Credit rating BB0 (average), no material lawsuits
No shareholder return initiatives (dividends or share buyback) disclosed